- Home
- IMRN vs TENX Comparison
IMRN vs TENX Comparison
Compare IMRN & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- TENX
- Stock Information
- Founded
- IMRN 1994
- TENX 1967
- Country
- IMRN Australia
- TENX United States
- Employees
- IMRN N/A
- TENX N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- TENX Health Care
- Exchange
- IMRN Nasdaq
- TENX Nasdaq
- Market Cap
- IMRN 9.2M
- TENX 21.6M
- IPO Year
- IMRN N/A
- TENX N/A
- Fundamental
- Price
- IMRN $1.74
- TENX $5.89
- Analyst Decision
- IMRN Strong Buy
- TENX Strong Buy
- Analyst Count
- IMRN 1
- TENX 3
- Target Price
- IMRN $5.00
- TENX $16.00
- AVG Volume (30 Days)
- IMRN 23.5K
- TENX 41.3K
- Earning Date
- IMRN 07-15-2025
- TENX 08-12-2025
- Dividend Yield
- IMRN N/A
- TENX N/A
- EPS Growth
- IMRN N/A
- TENX N/A
- EPS
- IMRN N/A
- TENX N/A
- Revenue
- IMRN $4,048,286.00
- TENX N/A
- Revenue This Year
- IMRN N/A
- TENX N/A
- Revenue Next Year
- IMRN N/A
- TENX N/A
- P/E Ratio
- IMRN N/A
- TENX N/A
- Revenue Growth
- IMRN 82.90
- TENX N/A
- 52 Week Low
- IMRN $1.50
- TENX $2.80
- 52 Week High
- IMRN $2.87
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- IMRN 48.56
- TENX 54.56
- Support Level
- IMRN $1.67
- TENX $5.68
- Resistance Level
- IMRN $1.78
- TENX $5.98
- Average True Range (ATR)
- IMRN 0.10
- TENX 0.48
- MACD
- IMRN -0.01
- TENX 0.01
- Stochastic Oscillator
- IMRN 49.97
- TENX 44.68
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.